The Week

Revvity (RVTY) rose 15.4% this week to $143.45, while the S&P 500 slipped 0.08%, leaving the stock about 15.48 percentage points ahead of the index. Day by day, the stock opened Monday at $124.69 and edged higher, then surged more than 9% on Tuesday. It pushed to a weekly high of $149.52 on Thursday before easing back to $143.45 by Friday, marking a rally that faded late in the week. Weekly amplitude was 20.51%, and average daily volume of roughly 3.0m shares was about double the median.

Key Events

The week’s main company story was around transformation, margin expansion and digital leadership in life sciences. Early in the week, commentary highlighted RVTY’s drive in these areas, and on Tuesday the stock outperformed peers in a strong session. By Wednesday it was listed among biotech names up 8%, with a MACD golden cross raising the question of whether momentum could continue. Thursday brought a look at long-term return potential. After Friday’s close, CFRA downgraded RVTY on limited near-term upside, and the stock slipped; the same day, SVP Global Operations Tajinder S. Vohra sold 7,330 shares worth about $1.03m, and RVTY underperformed competitors on Friday.

Analyst Ratings

As of 16 September 2026, 19 institutions rated RVTY: 6 buy, 12 hold and 1 under, with no sell or overweight. The consensus rating is buy, while the consensus target sits at $126.12, about 12.08% below the latest price. Targets range from $100 to $165, a wide spread. RVTY ranks 8th among 54 stocks in the life sciences tools and services industry.

The Week Ahead

Next week’s macro calendar runs from 22 to 24 September, including the Richmond Fed composite index, EIA crude and Cushing stock data, initial jobless claims, the current account balance, new home sales and natural gas inventories. After the CFRA downgrade, attention turns to whether RVTY can absorb the recent run-up, and whether more brokers adjust their views on the stock’s near-term path.

In Short

The strong weekly gain tracked the transformation narrative and a broader biotech move higher, but CFRA’s downgrade, an insider sale and a consensus target below the current price add opposite signals. Latest valuations show a P/E of roughly 67x, and the latest session’s fund flows pointed to net small-lot buying against large-lot selling. The key to watch is whether the rating divergence widens and which direction the stock takes after trading near recent highs.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.